Abstract: The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

Abstract: Nucleic acid sequences encoding the Bovine Coronavirus E2 (or BCV S) and E3 (or BCV HE) structural glycoproteins and methods of producing these proteins, including recombinant expression, e.g., in mammalian or insect cells, are provided. The E2 and E3 proteins or antigenic fragments thereof are useful components for Bovine Coronavirus vaccines and methods of treatment.

Abstract: Bovine coronavirus (BCV) E2 and E3 coding sequences and materials for producing the proteins E2 and E3 are provided. E2, E3, or antigenic fragments thereof are useful components for a BCV vaccine.

Abstract: New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are disclosed. The chimeric proteins include at least one epitope of leukotoxin fused to an active fragment of a cytokine. The chimeric proteins can be used in a vaccine composition. Also disclosed are methods of vaccination as well as methods of making the proteins employed in the vaccines.